Name
Pure erythroid leukemia
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C421
Primary site must be bone marrow (C421)
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
If the leukemia occurs before or simultaneously with Myeloid Sarcoma (9930/3), see M3 and Module 5:PH10.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
See abstractor notes
Alternate Names
Definition
Pure erthyroid leukemia is a neoplastic proliferation of immature cells (undifferentiated or proerythroblastic in appearance) committed exclusively to the erythroid lineage (> 80% of the bone marrow cells are erythroid, with greater than or equal to 30% proerythroblasts), with no evidence of a significant myeloblastic component.
Definitive Diagnostic Methods
Bone marrow biopsy
Immunophenotyping
Peripheral blood smear
Genetics Data
None
Immunophenotyping
CD71+ (expression/positive)
CD34- (no expression/negative)
CD36+ (expression/positive)
CD41- (no expression/negative)
CD61- (no expression/negative)
E-cadherin+ (expression/positive)
HLA-DR- (no expression/negative)
KIT (CD117)+ (expression/positive)
Treatments
Chemotherapy
Hematologic Transplant and/or Endocrine Procedures
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
207.0 Acute erythremia and erythroleukemia
Corresponding ICD-10 Codes
C94.0 Acute erythremia and erythroleukemia
Corresponding ICD-10-CM Codes (U.S. only)
C94.0 Acute erythroid leukemia (effective October 01, 2015)
Signs and Symptoms
Anemia
Circulating erythroblasts
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Age: predominantly adults
Incidence: <5% of all AML cases
Survival: poor, aggressive clinical course
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 161-162
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Acute myeloid leukemia and related precursor neoplasms
Pages: 161-162
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq
Section: General Information About Acute Myeloid Leukemia
Pages: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq